Zydus launches Bemdac to treat uncontrolled LDL-Cholesterol in India

New Delhi: Zydus Lifesciences has launched Bemdac® (Bempedoic acid), a new class of drug for the first time in India. The oral drug ushers in a new line of treatment for patients suffering from uncontrolled levels of LDL-Cholesterol (LDL-c) despite life-style modifications and the use of maximum tolerated dose of statins, which form the cornerstone of dyslipidemia management.

LDL-c is often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels, increasing the chances of health problems like heart attack or stroke. Uncontrolled LDL-c is a major risk factor for developing cardiovascular diseases. According to studies, 8 out of 10 Indians are dyslipidemic1 and 112 million adults suffer from high levels of LDL-c.

7 out of 10 dyslipidemia patients who are on statin treatment continue to suffer from
uncontrolled LDL-c. Besides this, 5.4 million Indians are found to be intolerant to statin
therapy.

Bempedoic acid has also shown to have good results in patients not able to tolerate
statins and those who do not respond to statins. This is a huge unmet healthcare need which Bemdac® addresses.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences said
“With Bemdac® we are happy to introduce a first-in-India therapy to address the unmet medical need of people suffering from uncontrolled LDL-c. Bemdac® is an important addition to Zydus’ portfolio of medicines for managing dyslipidemia and cholesterol. Our mission is to empower patients with a better quality of life through effective disease management and with Bemdac® we have taken a great leap ahead in this endeavour.”

Zydus has several leading brands to address cardiac care and dyslipidemia. This includes
Atorva®, Clopitorva®, Zyrova® and Pivasta®. The company’s brand Atorva® is a leader in the Atorvastatin market with a market share of 18.4%. The brand is also ranked second in terms of market share in the Rs. 2162 crore statin segment (AWACS Report Feb’22).